AroCell AB (AROC) - Net Assets

Latest as of March 2025: Skr108.87 Million SEK ≈ $11.72 Million USD

Based on the latest financial reports, AroCell AB (AROC) has net assets worth Skr108.87 Million SEK (≈ $11.72 Million USD) as of March 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr122.88 Million ≈ $13.22 Million USD) and total liabilities (Skr14.01 Million ≈ $1.51 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read AROC total debt and obligations for a breakdown of total debt and financial obligations.

Key Net Assets Metrics

Metric	Value
Current Net Assets	Skr108.87 Million
% of Total Assets	88.6%
Annual Growth Rate	31.65%
5-Year Change	115.43%
10-Year Change	66.73%
Growth Volatility	120.66

AroCell AB - Net Assets Trend (2007–2024)

This chart illustrates how AroCell AB's net assets have evolved over time, based on quarterly financial data. Also explore total assets of AroCell AB for the complete picture of this company's asset base.

Annual Net Assets for AroCell AB (2007–2024)

The table below shows the annual net assets of AroCell AB from 2007 to 2024. For live valuation and market cap data, see AROC company net worth.

Year	Net Assets	Change
2024-12-31	Skr121.20 Million ≈ $13.04 Million	-25.94%
2023-12-31	Skr163.65 Million ≈ $17.61 Million	-26.52%
2022-12-31	Skr222.69 Million ≈ $23.97 Million	+2.41%
2021-12-31	Skr217.45 Million ≈ $23.40 Million	+286.52%
2020-12-31	Skr56.26 Million ≈ $6.05 Million	-30.03%
2019-12-31	Skr80.41 Million ≈ $8.65 Million	+47.50%
2018-12-31	Skr54.51 Million ≈ $5.87 Million	+16.78%
2017-12-31	Skr46.68 Million ≈ $5.02 Million	-26.44%
2016-12-31	Skr63.46 Million ≈ $6.83 Million	-12.70%
2015-12-31	Skr72.69 Million ≈ $7.82 Million	+103.50%
2014-12-31	Skr35.72 Million ≈ $3.84 Million	+126.49%
2013-12-31	Skr15.77 Million ≈ $1.70 Million	+55.38%
2012-12-31	Skr10.15 Million ≈ $1.09 Million	+111.60%
2011-12-31	Skr4.80 Million ≈ $516.22K	+298.14%
2010-12-31	Skr1.20 Million ≈ $129.66K	+303.52%
2009-12-31	Skr-592.00K ≈ $-63.71K	-201.02%
2008-12-31	Skr586.00K ≈ $63.06K	-48.14%
2007-12-31	Skr1.13 Million ≈ $121.61K	--

Equity Component Analysis

This analysis shows how different components contribute to AroCell AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have decreased by 34284600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2024)

Component	Amount	Percentage
Common Stock	Skr23.04 Million	19.01%
Other Components	Skr441.01 Million	363.87%
Total Equity	Skr121.20 Million	100.00%

AroCell AB Competitors by Market Cap

The table below lists competitors of AroCell AB ranked by their market capitalization.

Company	Market Cap
VOGO SA PA:ALVGO	$13.39 Million
Sarama Resource V:SWA	$13.40 Million
Inepar S.A. Indústria e Construções SA:INEP3	$13.40 Million
Turk Ilac ve Serum Sanayi AS IS:TRILC	$13.41 Million
Tellusgruppen AB ST:TELLUS	$13.38 Million
Future Retail Limited NSE:FRETAIL	$13.37 Million
Indian Card Clothing Company Limited NSE:INDIANCARD	$13.37 Million
SAIHEAT Limited NASDAQ:SAIH	$13.37 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in AroCell AB's equity between the two most recent reporting periods.

Equity Growth Insights

From 2023 to 2024, total equity changed from 163,646,000 to 121,198,000, a change of -42,448,000 (-25.9%).
Net loss of 42,449,000 reduced equity.

Equity Change Factors (2023 to 2024)

Factor	Impact	Contribution
Net Income	Skr-42.45 Million	-35.02%
Other Changes	Skr1.00K	+0.0%
Total Change	Skr-	-25.94%

Book Value vs Market Value Analysis

This analysis compares AroCell AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 1.03x
The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
The price-to-book ratio has decreased from 2.23x to 1.03x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2010-12-31	Skr0.24	Skr0.54	x
2011-12-31	Skr0.57	Skr0.54	x
2012-12-31	Skr0.69	Skr0.54	x
2013-12-31	Skr0.82	Skr0.54	x
2014-12-31	Skr1.46	Skr0.54	x
2015-12-31	Skr2.45	Skr0.54	x
2016-12-31	Skr2.14	Skr0.54	x
2017-12-31	Skr1.57	Skr0.54	x
2018-12-31	Skr1.34	Skr0.54	x
2019-12-31	Skr2.00	Skr0.54	x
2020-12-31	Skr0.75	Skr0.54	x
2021-12-31	Skr2.22	Skr0.54	x
2022-12-31	Skr1.03	Skr0.54	x
2023-12-31	Skr0.71	Skr0.54	x
2024-12-31	Skr0.53	Skr0.54	x

Capital Efficiency Dashboard

This dashboard shows how efficiently AroCell AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): -35.02%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: -73.91%
• Asset Turnover: 0.43x
• Equity Multiplier: 1.11x
Recent ROE (-35.02%) is above the historical average (-40.12%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2010	-178.64%	-8014.58%	0.01x	3.02x	Skr-2.27 Million
2011	-74.72%	0.00%	0.00x	1.46x	Skr-4.06 Million
2012	-31.10%	0.00%	0.00x	1.18x	Skr-4.17 Million
2013	-23.67%	0.00%	0.00x	1.14x	Skr-5.31 Million
2014	-17.83%	0.00%	0.00x	1.08x	Skr-9.94 Million
2015	-10.29%	-1625.10%	0.01x	1.02x	Skr-14.75 Million
2016	-14.55%	-16911.96%	0.00x	1.05x	Skr-15.58 Million
2017	-37.00%	-3440.16%	0.01x	1.06x	Skr-21.94 Million
2018	-38.08%	-2654.89%	0.01x	1.05x	Skr-26.21 Million
2019	-20.15%	-3659.83%	0.00x	1.14x	Skr-24.24 Million
2020	-34.59%	-23165.48%	0.00x	1.07x	Skr-25.08 Million
2021	-23.43%	-417.02%	0.05x	1.07x	Skr-71.38 Million
2022	-26.48%	-159.45%	0.16x	1.06x	Skr-81.24 Million
2023	-36.23%	-137.78%	0.25x	1.07x	Skr-75.66 Million
2024	-35.02%	-73.91%	0.43x	1.11x	Skr-54.57 Million

Industry Comparison

This section compares AroCell AB's net assets metrics with peer companies in the Diagnostics & Research industry.

Industry Context

Industry: Diagnostics & Research
Average net assets among peers: $167,706,768
Average return on equity (ROE) among peers: -28.61%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
AroCell AB (AROC)	Skr108.87 Million	-178.64%	0.13x	$13.39 Million
Devyser Diagnostics AB (DVYSR)	$431.44 Million	-10.65%	0.16x	$168.47 Million
Immunovia publ AB (IMMNOV)	$243.80 Million	-59.49%	0.23x	$14.70 Million
Prostatype Genomics AB (PROGEN)	$35.91 Million	-43.53%	0.12x	$4.83 Million
SenzaGen AB (SENZA)	$107.79 Million	-25.34%	0.03x	$17.21 Million
Vimian Group AB (VIMIAN)	$19.59 Million	-4.03%	0.70x	$1.70 Billion

About AroCell AB

ST:AROC Sweden Diagnostics & Research

Market Cap

$13.39 Million

Skr124.39 Million SEK

Market Cap Rank

#26150 Global

#556 in Sweden

Share Price

Skr0.54

Change (1 day)

+1.12%

52-Week Range

Skr0.50 - Skr0.60

All Time High

Skr15.05